Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705193 | 0.86 | KMT2A (0.55) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL28845231 | 0.86 | KMT2A (0.55) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL21113593 | 0.86 | KMT2A (0.55) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL20420223 | 0.85 | KAT2B (0.70) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL20419961 | 0.85 | ALDH1A1 (0.57) | KAT2BMAPTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL20797515 | 0.84 | KMT2A (0.53) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL21751587 | 0.82 | MAPT (0.62) | KAT2BMAPTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL21751550 | 0.82 | MAPT (0.62) | KAT2BMAPTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL21751639 | 0.82 | MAPT (0.62) | KAT2BMAPTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL20420113 | 0.82 | KAT2B (0.53) | KAT2BMAPTSMN1; SMN2KMT2AHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199174-A1 | NOVEL FLUORESCENT LABELING METHOD | THE UNIVERSITY OF TOKYO (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20200199174-A1 | NOVEL FLUORESCENT LABELING METHOD | THE UNIVERSITY OF TOKYO (JP) | 2020-06-25 | — | — | US | disclosed |
| WO-2018135598-A1 | NOVEL FLUORESCENT LABELING METHOD | 国立大学法人 東京大学 | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199174-A1 | NOVEL FLUORESCENT LABELING METHOD | RPS27A, DNPEP, DNM1L | KAT2B 2802/4885MAPT 1510/4885SMN1; SMN2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.